Compare GT & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GT | MLTX |
|---|---|---|
| Founded | 1898 | 2021 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Automotive Aftermarket | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | 2005 | 2020 |
| Metric | GT | MLTX |
|---|---|---|
| Price | $6.85 | $20.79 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 12 |
| Target Price | $9.13 | ★ $27.50 |
| AVG Volume (30 Days) | ★ 11.3M | 1.4M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $18,280,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.06 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.43 | $5.95 |
| 52 Week High | $11.65 | $62.75 |
| Indicator | GT | MLTX |
|---|---|---|
| Relative Strength Index (RSI) | 58.04 | 61.85 |
| Support Level | $6.61 | $15.54 |
| Resistance Level | $7.40 | $21.00 |
| Average True Range (ATR) | 0.32 | 1.11 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 74.17 | 46.79 |
Goodyear Tire & Rubber Co manufactures and sells a variety of rubber tires under the Goodyear brand name. The firm's tires are used for automobiles, trucks, buses, aircraft, motorcycles, mining equipment, farm equipment, and industrial equipment. The company operates its business through three operating segments representing its regional tire businesses: Americas; Europe, the Middle East, and Africa (EMEA); and the Asia Pacific. The majority of its revenue is generated from the Americas business, which develops, manufactures, distributes, and sells tires and related products and services in North, Central, and South America, along with selling tires to various export markets, mainly through intersegment sales.
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.